Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference

Kairos Pharma, LTD.

Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.
Presentation at World Lung Cancer Conference in Barcelona, Spain, September 6-9, 2025.
Primary objective of open-label Phase 1 trial is to evaluate safety and tolerability of the combination.
ENV105 targets CD105 to reverse drug resistance; also in Phase 2 for castrate-resistant prostate cancer.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.